Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07539103
Starting soon Observational

VIRal Pulmonary Infections in Older AGE

NCT07539103 · tracked via the Priya Life Science France tracker
Sponsor
Gérond'if
Phase
Observational
Started
2026-06-01
Last updated
2026-04-20

Condition(s) studied

Viral Pulmonary Infections

Study summary

Severe acute respiratory infections (SARIs) represent one of the leading causes of hospitalization and mortality worldwide. These infections are associated with substantial in-hospital mortality and often constitute a turning point in the medium-term prognosis of older patients and those with comorbid conditions.

SARIs are most frequently of viral origin, involving well-known pathogens such as Orthomyxoviridae (influenza A and B viruses), Pneumoviridae \[(respiratory syncytial virus (RSV), human metapneumovirus (hMPV)\], Paramyxoviridae \[parainfluenza viruses (PIV)\], adenoviruses, or rhinoviruses, as well as emerging viruses such as pandemic influenza strains and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic.

Age-related immune decline (immunosenescence) increases the risk of severe forms and related respiratory or cardiovascular complications. However, the prevalence and burden of the different viral etiologies of Severe acute respiratory infections (SARIs) in older adults remain limited and insufficiently characterized.

The primary objective is to determine the proportion of viral respiratory infections attributable to polymerase chain reaction (PCR)-confirmed pathogen agents among hospitalized older subjects (≥60 years old).

Eligibility

Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Hospitalized subjects aged ≥ 60 years * A respiratory sample collected and tested by polymerase chain reaction (PCR) during hospitalisation as part of standard of care Note: Reasons for PCR: 1. Patients with Severe acute respiratory infection (SARI) 2. Patients with symptoms other than SARI 3. Systematic PCR testing (in the context of clusters or during the winter season) \* Recent onset of at least one general symptom and at least one functional or physical respiratory sign * General symptoms: fever (which may be absent in older patients), chills, sweating, headache, malaise, myalgia, arthralgia, fatigue, decline in general condition (asthenia, weight loss, anorexia, confusion, or dizziness), digestive disturbances. * Respiratory signs: sore throat, rhinorrhoea (common cold), cough, wheezing, dyspnoea, chest pain, or recent auscultatory abnormalities (diffuse or focal). * Subjects willing to participate, with a non-opposition form completed and signed by the qualified and trained healthcare professional responsible for providing the participant information * Subject affiliated to a health insurance system Exclusion Criteria: * Subjects refusing to participate * Subjects admitted to palliative care unit. * Subjects under guardianship * Any condition that, in the opinion of the investigator, may interfere with the aim of the study or wellbeing of the patient

Primary outcome measure(s)

  • Number of RT-PCR-confirmed positive cases for viral pathogen agents of interest among hospitalized older subjects (≥60 years old) — At baseline

Trial sites (20)

FacilityCityRegionStatus
CHU Bordeaux Pessac Bordeaux
CHU Amiens Picardie Amiens France
Centre Hospitalier Départemental Vendée_La Roche sur Yon La Roche-sur-Yon France
CHU Nimes Nîmes France
Hôpital St Antoine Paris France
Hôpital Broca - APHP Paris France
Hôpital Avicenne APHP Bobigny Île-de-France Region
Hôpital Ambroise Paré-APHP Boulogne-Billancourt Île-de-France Region
Hôpital Henri Mondor APHP Créteil Île-de-France Region
Hôpital Corentin Celton APHP, Gérontologie 1 Issy-les-Moulineaux Île-de-France Region
Hôpital Corentin Celton APHP, Gérontologie 2 Issy-les-Moulineaux Île-de-France Region
Hôpital Charles Foix APHP Ivry-sur-Seine Île-de-France Region
CH de Versailles Le Chesnay Île-de-France Region
Hôpital Emile Roux APHP Limeil-Brévannes Île-de-France Region
HEGP Paris Île-de-France Region
Hôpital Bretonneau APHP Paris Île-de-France Region
Hôpital Sainte Périne Paris Île-de-France Region
Hôpital Lariboisière - APHP Paris Île-de-France Region
Hôpital Bichat-APHP Paris Île-de-France Region
Hôpital Paul Brousse APHP Villejuif Île-de-France Region

More Gérond'if trials in France

Determinant of the Risk of the Becoming Frail in the Non-dependent Elederly Recruiting
Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure Recruiting
Evaluation of Medical and Social Care for Elderly Patients, Between Hospital and Home: TEMPORARY ACCOMMODATION Out of Hospitalization by Nursing Home and Long-Term Care Units in Ile-de-France Region Recruiting
Relevance of Artificial Intelligence-Assisted Echocardiography for Left Ventricular Ejection Fraction Assessment in Geriatric Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07539103 on ClinicalTrials.gov ↗ ← All trials in France